News
(LU-PSMA) Phase 1 Trial - Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC Overall survival and response pattern of castration-resistant metastatic prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback